A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

NCT04995042 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hormone Sensitive Prostate Cancer

Interventions

DRUG: SHR7280

Sponsor

Jiangsu HengRui Medicine Co., Ltd.